Principles for Management of Extractables and Leachables in Ophthalmic Drug Products

References

1. 1.↵
   U.S. Food and Drug Administration, Guidance for Industry: Container Closure Systems for Packaging Human Drugs and Biologics, Center for Biologics Evaluation and Research, U.S. Department of Health and Human Services: Rockville, MD, 1999.
2. 2.↵
   U.S. Pharmacopeial Convention, General Chapter <1664> Assessment of Drug Product Leachables Associated with Pharmaceutical Packaging/Delivery Systems. In USP 38 –NF 33, USP: Rockville, MD, 2015.
3. 3.↵
   Product Quality Research Institute Leachables and Extractables Working Group. Safety Thresholds and Best Practices for Extractables and Leachables in Orally Inhaled and Nasal Drug Products. PQRI, 2006.
4. 4.↵
   1. Paskiet D.,
   2. Jenke D.,
   3. Ball D.,
   4. Houston C.,
   5. Norwood D. L.,
   6. Markovic I.

   The Product Quality Research Institute (PQRI) Leachables and Extractables Working Group Initiatives for Parenteral and Ophthalmic Drug Product (PODP). PDA J. Pharm. Sci. Technol. 2013, 67 (5), 430–447.

   OpenUrlAbstract/FREE Full Text
5. 5.↵
   Product Quality Research Institute Parenteral and Ophthalmic Drug Product Leachables and Extractables Working Group. Safety Thresholds and Best Demonstrated Practices for Extractables and Leachables in Parenteral Drug Products (Intravenous, Subcutaneous, and Intramuscular). PQRI, 2021.
6. 6.↵
   International Conference on Harmonisation, Quality Guideline Q3B9R2): Impurities in New Drug Products. ICH: Geneva, 2006.
7. 7.↵
   European Medicines Agency, Guideline on Plastic Immediate Packaging Materials. EMA: London, 2005.
8. 8.↵
   International Conference on Harmonisation, ICH Harmonised Guideline M7(R1). Assessment and Control of DNA Reactive (Mutagenic) Impurities in Pharmaceuticals to Limit Potential Carcinogenic Risk. ICH: Geneva, 2018
9. 9.↵
   1. Ng L.

   Current Regulatory Recommendations for Leachables in Ophthalmic Products, Product Quality Research Institute Workshop on Thresholds and Best Practices for Parenteral and Ophthalmic Drug Products (PODP), Bethesda, MD, February 22–23, 2011.
10. 10.↵
    1. Urtti A.,
    2. Salminen L.

    Minimizing Systemic Absorption of Topically Administered Ophthalmic Drugs. Surv. Ophthalmol. 1993, 37 (6), 435–456.

    OpenUrlCrossRefPubMed
11. 11.↵
    1. Pan C.,
    2. Harmon F.,
    3. Toscano K.,
    4. Liu F.,
    5. Vivilecchia R.

    Strategy for Identification of Leachables in Packaged Pharmaceutical Liquid Formulations. J Pharm. Biomed. Anal. 2008, 46 (3), 520–527.

    OpenUrlPubMed
12. 12.↵
    1. Jenke D.,
    2. Egert T.,
    3. Hendricker A.,
    4. Castner J.,
    5. Feinberg T.,
    6. Houston C.,
    7. Hunt D. G.,
    8. Lynch M.,
    9. Nicholas K.,
    10. Norwood D. L.,
    11. Paskiet D.,
    12. Ruberto M.,
    13. Smith E. J.,
    14. Holcomb F.,
    15. Markovic I.

    Simulated Leaching (Migration) Study for a Model Container-Closure System Applicable to Parenteral and Ophthalmic Drug Products. PDA J. Pharm. Sci. Technol. 2017, 71 (2), 68–87.

    OpenUrlAbstract/FREE Full Text
13. 13.↵
    1. Jenke D.,
    2. Castner J.,
    3. Egert T.,
    4. Feinberg T.,
    5. Hendricker A.,
    6. Houston C.,
    7. Hunt D. G.,
    8. Lynch M.,
    9. Shaw A.,
    10. Nicholas K.,
    11. Norwood D. L.,
    12. Paskiet D.,
    13. Ruberto M.,
    14. Smith E. J.,
    15. Holcomb F.

    Extractables Characterization for Five Materials of Construction Representative of Packaging Systems Used for Parenteral and Ophthalmic Drug Products. PDA J. Pharm. Sci. Technol. 2013, 67 (5), 448–511.

    OpenUrlAbstract/FREE Full Text
14. 14.↵
    1. Haider N.,
    2. Karlsson S.

    Loss and Transformation Products of the Aromatic Antioxidants in MDPE Film under Long-Term Exposure to Biotic and Abiotic Conditions. J. Appl. Polym. Sci. 2002, 85 (5), 974–988.

    OpenUrl
15. 15.↵
    1. Bertoldo M.,
    2. Ciardelli F.

    Water Extraction and Degradation of a Sterically Hindered Phenolic Antioxidant in Polypropylene Films. Polymer 2004, 45 (26), 8751–9759.

    OpenUrl
16. 16.↵
    1. Caspi R. R.

    Understanding Autoimmunity in the Eye: From Animal Models to Novel Therapies. Discov. Med. 2014, 17 (93), 155–162.

    OpenUrlPubMed
17. 17.↵
    1. Freddo T. F.

    A Contemporary Concept of the Blood-Aqueous Barrier. Prog. Retin. Eye Res. 2013, 32, 181–195.

    OpenUrlCrossRefPubMed
18. 18.↵
    1. O'Donnell B. F.,
    2. Foulds I. S.

    Contact Allergic Dermatitis and Contact Urticaria Due to Topical Ophthalmic Preparations. Br. J. Ophthalmol. 1993, 77 (11), 740–741.

    OpenUrlFREE Full Text
19. 19.↵
    1. Chaudhari P. R.,
    2. Maibach H. I.

    Allergic Contact Dermatitis from Ophthalmics: 2007. Contact Dermatitis 2007, 57 (1), 11–13.

    OpenUrlPubMed
20. 20.↵
    1. Baeck M.,
    2. De Potter P.,
    3. Goossens A.

    Allergic Contact Dermatitis following Ocular Use of Corticosteroids. J. Ocul. Pharmacol. Ther. 2011, 27 (1), 83–92.

    OpenUrlPubMed
21. 21.↵
    1. Landeck L.,
    2. John S. M.,
    3. Geier J.

    Topical Ophthalmic Agents as Allergens in Periorbital Dermatitis. Br. J. Ophthalmol. 2014, 98 (2), 259–262.

    OpenUrlAbstract/FREE Full Text
22. 22.↵
    1. Gerberick G. F.,
    2. Robinson M. K.,
    3. Ryan C. A.,
    4. Dearman R. J.,
    5. Kimber I.,
    6. Basketter D. A.,
    7. Wright Z.,
    8. Marks J. G.

    Contact Allergenic Potency: Correlation of Human and Local Lymph Node Assay Data. Am. J. Contact Dermat. 2001, 12 (3), 156–161.

    OpenUrlCrossRefPubMed
23. 23.↵
    1. Jowsey I. R.

    Proactive Surveillance of Contact Allergies: An Important Component of the Risk Management Strategy for Skin Sensitizers. Contact Dermatitis 2007, 56 (6), 305–310.

    OpenUrlPubMed
24. 24.↵
    1. Basketter D. A.,
    2. Clapp C. J.,
    3. Safford B. J.,
    4. Jowsey I. R.,
    5. McNamee P.,
    6. Ryan C. A.,
    7. Gerberick G. F.

    Preservatives and Skin Sensitization Quantitative Risk Assessment. Dermatitis 2008, 19 (1), 20–27.

    OpenUrlPubMed
25. 25.↵
    1. Teubner W.,
    2. Mehling A.,
    3. Schuster P. X.,
    4. Guth K.,
    5. Worth A.,
    6. Burton J.,
    7. van Ravenzwaay B.,
    8. Landsiedel R.

    Computer Models versus Reality: How Well Do in Silico Models Currently Predict the Sensitization Potential of a Substance. Regul. Toxicol. Pharmacol. 2013, 67 (3), 468–485.

    OpenUrl
26. 26.↵
    1. Patlewicz G.,
    2. Aptula A. O.,
    3. Uriarte E.,
    4. Roberts D. W.,
    5. Kern P. S.,
    6. Gerberick G. F.,
    7. Kimber I.,
    8. Dearman R. J.,
    9. Ryan C. A.,
    10. Basketter D. A.

    An Evaluation of Selected Global (Q)SARs/Expert Systems for the Prediction of Skin Sensitization Potential. SAR QSAR Environ. Res. 2007, 18 (5-6), 515–541.

    OpenUrlCrossRefPubMedWeb of Science
27. 27.↵
    1. Roberts D. W.,
    2. Aptula A. O.,
    3. Patlewicz G.

    Mechanistic Applicability Domains for Non-Animal-Based Prediction of Toxicological Endpoints. QSAR Analysis of the Schiff Base Applicability Domain for Skin Sensitization. Chem. Res. Toxicol. 2006, 19 (9), 1228–1233.

    OpenUrlCrossRefPubMedWeb of Science
28. 28.↵
    1. Roberts D. W.,
    2. Patlewicz G.,
    3. Kern P. S.,
    4. Gerberick F.,
    5. Kimber I.,
    6. Dearman R. J.,
    7. Ryan C. A.,
    8. Basketter D. A.,
    9. Aptula A. O.

    Mechanistic Applicability Domain Classification of a Local Lymph Node Assay Dataset for Skin Sensitization. Chem. Res. Toxicol. 2007, 20 (7), 1019–1030. Jul

    OpenUrlCrossRefPubMedWeb of Science
29. 29.↵
    1. Sacca S. C.,
    2. Bolognesi C.,
    3. Battistella A.,
    4. Bagnis A.,
    5. Izzotti A.

    Gene-Environment Interactions in Ocular Diseases. Mutat. Res., Fundam. Mol. Mech. Mutagen. 2009, 667 (1–2), 98–117.

    OpenUrl
30. 30.↵
    1. Kroes R.,
    2. Kleiner J.,
    3. Renwick A.

    The Threshold of Toxicological Concern Concept in Risk Assessment. Toxicol. Sci. 2005, 86 (2), 226–230.

    OpenUrlCrossRefPubMedWeb of Science